T-cell immunoreceptor with Ig and ITM domain (TIGIT) is novel immunological checkpoint which is being studied as potential immunotherapeutic target.
Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:
- Global TIGIT Inhibitor Market Dynamics
- Clinical Approaches to Target TIGIT
- Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Clinical Trials Adverse Events Scenario
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global TIGIT Inhibitor Market Future Outlook
Download Report:
T-cell immunoreceptor with Ig and ITM domain (TIGIT) is novel immunological checkpoint which is being studied as potential immunotherapeutic target. Recent research activities have identified TIGIT as promising emerging immune checkpoint target. TIGIT indirectly suppresses the T-cell activation and is expressed on multiple types of immune cells, including regulatory T-cell, activated T-cell, and natural killer cell. The expression of TIGIT is associated with the advanced disease, disease recurrence, and poor survival outcomes. Thus, researchers have designed several approaches to target TIGIT for the management of cancer.
The promising preclinical activities of targeting TIGIT in cancer have encouraged the pharmaceutical companies to develop novel TIGIT inhibitor. In January 2021, Genentech has announced that Tiragolumab, a novel cancer immunotherapy targeting TIGIT has received breakthrough therapy designation from US FDA in combination with Tecentriq for the management of non-small cell lung cancer. Tiragolumab represents one of the most advanced TIGIT inhibitor in clinical development. The other potential TIGIT inhibitor in clinical development includes Ociperlimab, Vibostolimab, ASP-8374, AGEN1777, HLX301, and COM902. These inhibitors have shown promising response in clinical trials and are expected to gain entry into the market during the forecast period.
Due to continuous technology advances in research and development in the field of oncology and the requirement for newer and more effective pharmaceutical drugs/therapies, companies are investing in the development of these new products to lessen the side effects and target the disease. The global TIGIT inhibitor market is highly competitive and consists of major key players including Acrus Bioscience, AstraZeneca, Roche, Seagen, iTeos Therapeutics, Gilead Sciences, Compugen, Bristol Myers Squibb, Merck, and others. Since the identification of TIGIT as potential target in the management of cancer, several pharmaceutical companies have adopted strategic alliances such as collaboration, partnership, or joint ventures to drive the growth of market.
For instance in 2022, Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the US and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement. Further in June 2021, GlaxoSmithKline and iTeos Therapeutics announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. Apart from this, Bristol Myers Squibb purchased an exclusive license to Agenus’ AGEN1777, a bispecific antibody that blocks TIGIT and a second undisclosed target. These rising trends in the global market suggest the promising future of TIGIT inhibitor in the management of cancer.
It is estimated that there are currently more than 50 ongoing clinical trials which are accessing the role of novel TIGIT inhibitors in wide range of cancers and several studies are being conducted at preclinical level. US is expected to dominate the global TIGIT inhibitor which is mainly due to large number of ongoing clinical trials and presence of major pharmaceutical giants in the region. Apart from this, increasing awareness among the individuals, high adoption rates of immunotherapeutic drugs, favorable reimbursement policies, and increasing initiatives by government will also drive the growth of the market in the region.
The rising awareness regarding cancer and availability of various immunotherapeutic approaches and innovative diagnostic tools for detecting cancer will boost the global TIGIT inhibitor market. The rising investments by the biopharmaceutical industry players in the research and clinical trials of various therapeutics and diagnostics will further drive the growth of market during the forecast period.. The report provides comprehensive analysis on the ongoing clinical trials and ongoing partnerships and agreements among key players. In addition, the report provides insights into potential role of TIGIT inhibitor in cancer, HIV, and other autoimmune disorders.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366